For this volume of Advances in Pharmacology we have brought together some of the foremost basic science and clinical researchers to discuss some of the new frontiers in the development of targeted cancer therapy. Although still in its formative stages, the development of targeted cancer therapies has already shown incredible promise in a limited number of cancer types. As basic cancer research and drug development continues, we expect this number to grow and more patients to benefit from these exciting advances. Through better patient selection and novel strategies to manage resistance, a future can be envisaged in which cancer can be reduced to the level of a chronic, manageable disease.

Key Features

  • Brought together some of the foremost basic science and clinical researchers
  • Part of the renowned Advances in Pharmacology Serial
  • Discussion of some of the new frontiers in the development of targeted cancer therapy


Pharmacologists, immunologists, and biochemists

Table of Contents



Chapter One Vertical Pathway Targeting in Cancer Therapy

1 Introduction

2 Mitogenic Signaling in Cancer

3 Monoclonal Antibodies and Small Molecule Inhibitors Targeting Oncogenic Signaling in Cancer

4 Targeting of Parallel Signaling Pathways

5 Vertical Pathway Targeting

6 Conclusion

Chapter Two Histone Deacetylases (HDACs) as Mediators of Resistance to Apoptosis in Melanoma and as Targets for Combination Therapy with Selective BRAF Inhibitors

1 Introduction

2 HDACs in Melanoma

3 HDACs as Suppressors of Apoptosis

4 HDAC Inhibitors Reverse Resistance of Melanoma Cells to Induction of Apoptosis by Selective BRAF Inhibitors

5 Reversal of Resistance to PLX4720 is Associated with Changes in the Bcl-2 Family Proteins

6 Pan-HDAC Inhibitors Reverse the Resistance of Melanoma Cell Lines to Selective BRAF inhibitors: Multispecific versus Specific Agents in Reversal of Resistance to Selective BRAF Inhibitors

7 Conclusion


Chapter Three Targeting the Tumor Stroma as a Novel Treatment Strategy for Breast Cancer

1 Introduction

2 Exploiting the Multifaceted Roles of CAF in Tumor Progression in Development of Novel Therapeutic Strategies for TNBC

3 Future CAF Targeting Strategies

4 Conclusion


Chapter Four Targeting the Metabolic Microenvironment of Tumors

1 Introduction

2 Imaging the Tumor Microenvironment

3 Targeting Glucose Metabolism

4 Targeting Hypoxia

5 Targeting Acidosis

6 Manipulating the Microenvironment for Therapeutic Benefit

7 Conclusion

Non-standard Abbreviations

Chapter Five Targeted Therapy for Brain Metastases

1 Introduction

2 Lung Cancer

3 Breast Cancer

4 Melanoma

5 Conclusion


Chapter Six E


No. of pages:
© 2012
Academic Press
eBook ISBN:
Print ISBN:

About the serial-volume-editor